Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126278 · ClinicalTrials.gov registry record · Phase 4
Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection
A Phase 4 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT04126278: Clinical Trial Phase 4 study, sponsored by NYU Langone Health.
NCT04126278 is a Phase 4 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 4 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04126278, a Phase 4 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of barbotage therapy by comparing the clinical and sonographic changes in patients that solely receive barbotage to patients receiving the standard of care, barbotage with cortisone injection.
Primary Outcome
Pain will be assessed by the Visual Analog Scale which describes pain in terms of no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
Interventions
- DRUG Dexamethasone
- DRUG Barbotage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2022-08-23 |
| Phase | Phase 4 |
Why NCT04126278 stopped before completion
NCT04126278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT04126278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04126278 about?
NCT04126278 is a clinical study titled "Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection". The purpose of this study is to determine the efficacy of barbotage therapy by comparing the clinical and sonographic changes in patients that solely receive barbotage to patients receiving the standard of care, barbotage with cortisone injection.
What is the current status of trial NCT04126278?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2020-12-01. Estimated completion is 2022-08-23.
What interventions are being tested in trial NCT04126278?
The interventions under investigation include: Dexamethasone (DRUG), Barbotage (DRUG).
Who is sponsoring clinical trial NCT04126278?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04126278's enrollment target sits among peer trials
4 1994th of 2000 higher than 6 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI